Mobile Monoclonal Antibody Infusion Treatment
Monoclonal antibody infusion is among the most promising treatments for mild to moderate COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. Monoclonal antibodies are just like your body’s antibodies but are selected for their strong ability to resist the virus. Anyplace MD provides first and one-of-a-kind mobile antibody treatment.
APMD partners with hospitals across the United States to help fight COVID-19.
Why APMD Monoclonal antibody treatment
Clinical trials have shown that these treatments can decrease hospitalizations and emergency department visits. They can also reduce the amount of virus found in an infected person’s blood.
After entering your body, monoclonal antibodies look for and attach to the spike protein that sticks out of the coronavirus that causes COVID-19. When monoclonal antibodies attach to the spike protein, they can block the virus’s ability to enter cells — and slow down the infection.
Your Ultimate COVID-19 Treatment Solution
Health care workers administer monoclonal antibodies with a one-time intravenous (IV) infusion. The IV infusion involves placing a needle in a vein and gradually sending the medicine through the IV and into the body.
The infusion takes about an hour. After the IV is removed, patients must wait at least one more hour so health care workers can watch for side effects or negative reactions.
Mobile and Effective
We provide mobile monoclonal antibody infusion treatment in specialized mobile trailers or we can set up modular buildings to fit your needs
Monoclonal antibody treatment frequently asked questions
The most common reported side effects for bamlanivimab/etesevimab are:
- Difficulty breathing
- Rapid/slow heart rate
As we mentioned, APMD is the first organization that provides mobile solutions of your choice. Depending on your needs, we can either set up a modular building or have our special trailers with all the equipment to come to you.
In 2020, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to allow monoclonal antibodies as a treatment option for COVID-19.
People who have received a monoclonal antibody infusion for COVID-19 should not be vaccinated within 90 days of their infusion. These people are eligible when the monoclonal antibodies no longer affect the vaccine.
If you already received one or both doses of the vaccine and you are eligible, you can receive this treatment.
Check with your insurance provider for more information on the cost of monoclonal antibody treatment for COVID-19.